Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer

Published:2015-05 Issue:17 Volume:94 Page:e774
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Yuan Peng,Di Lijun,Zhang Xiaohui,Yan Min,Wan Donggui,Li Li,Zhang Yongqiang,Cai Jufen,Dai Hong,Zhu Qi,Hong Ruoxi,Xu Binghe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference24 articles.

1. Weekly schedule of vinorelbine in pretreated breast cancer patients;Nistico;Breast Cancer Res Treat,2000

2. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines;Talbot;Br J Cancer,2002

3. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane;Smorenburg;Breast Cancer Res Treat,2001

4. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma;Zelek;Cancer,2001

5. Single-agent gemcitabine is active in previously treated metastatic breast cancer;Spielmann;Oncology,2001

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Chemotherapy Optimization with Discrete Dosing;INFORMS Journal on Computing;2023-11-09

2. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study;The Tohoku Journal of Experimental Medicine;2023

3. Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals;Cancers;2022-04-24

4. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment;International Journal of Molecular Sciences;2021-12-17

5. Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer;Cancers;2021-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3